...Paola Barbarino Good morning, good afternoon, good evening, everybody. Thank you very much for joining us in the first webinar of our series of webinars for 2021. And boy, was the webinar we have was the first one, we have decided this time to tackle one of the most interesting issues in our field and area. We have invited Biogen to present that data on aducanumab. Now I'm going to tell you a little bit more about what we're going to speak about in the second slide and why we called this webinar. So Biogen, as many of you will know, is a multinational biotechnology company based in the U.S., which specializes in therapies for the treatment of neurological diseases. ADI has worked with Biogen for a number of years. They are interested, of course, in the fact that our membership includes the people that would be eventually beneficiary of what they are doing. We will hear from Biogen about the data from the Phase III clinical studies ENGAGE and EMERGE. But let me tell you a bit why we did...
